Hyderabad: Aurobindo Pharma Limited has announced that its wholly owned subsidiary, CuraTeQ Biologics Pvt Ltd, has entered into a marketing and distribution agreement with Germany-based pharmaceutical company STADA Arzneimittel AG for biosimilars in select European markets.Under the agreement, STADA will be responsible for the commercialization of two European Medicines Agency (EMA)-approved biosimilars developed by CuraTeQ. These products will be marketed across key European Union territories, including France and Germany, under newly created and registered brand names.Also Read: Aurobindo Pharma Gets 3 USFDA Observations for Apitoria Unit-V, Classified as VAIThe collaboration is expected to significantly strengthen CuraTeQ’s footprint in the European biosimilars market by leveraging STADA’s well-established distribution network. The partnership aims to enhance market penetration and support revenue growth for Aurobindo Pharma’s biologics segment.CuraTeQ Biologics, focused on biosimilars development, continues to expand its global reach through strategic alliances, aligning with Aurobindo Pharma’s broader vision of strengthening its presence in regulated markets.The company clarified that the agreement does not qualify as a material event under Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Also Read: Aurobindo’s Eugia Arm Secures USFDA Nod for Transplant Drug Everolimus